Compare Becton Dickinson and Co (BDX) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Visa Inc — how do they compare? Becton Dickinson and Co trades at $181.29 (market cap $48.93B), while Visa Inc trades at $362.71 (market cap $668.96B). The key difference: Visa Inc is far larger — about 13.7× Becton Dickinson and Co's market cap, and Becton Dickinson and Co pays the higher dividend (2.34%). Which is the better fit depends on your goals.
| BDX | V | |
|---|---|---|
Market Cap | $48.93B | $668.96B |
Sector | Health | Financials |
52-Week High | $185.39 | $370.47 |
52-Week Low | $138.62 | $295.52 |
Enterprise Value | $65.03B | $679.54B |
Dividend Yield | 2.34% | 0.74% |
Volume | — | 10,431,336 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX (Becton, Dickinson and Company) trades at $176.86, down 0.12% on the day, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported Q3 2026 revenue of $5.0 billion, up 4.4% FX-neutral, and raised full-year guidance, though margins faced pressure. Analyst sentiment is mixed with a consensus price target of $183.00, while institutional ownership remains stable amid positive news on GLP-1 therapy expansions and dividend declarations.
The stock offers steady growth potential with a 2.7% dividend yield and consistent earnings outperformance, but risks include margin compression, regulatory recalls, and high valuation multiples. Near-term resistance at $180 and support at $173 will test bullish momentum, with the current price near the consensus target suggesting limited upside without further catalysts.
Visa (V) trades at $362.82, up 0.09% on the day, with strong fundamentals including a 50.78% net income margin and consistent earnings beats. The stock is near-term bearish technically but supported by a bullish analyst consensus with a $426.31 price target. Recent news highlights Visa's expansion into AI-driven commerce and stablecoin partnerships, positioning it for future growth amid digital payment evolution.
Visa's outlook remains positive due to robust profitability, strategic tech initiatives, and Wall Street support, though risks include competitive fintech disruption and regulatory pressures. The stock offers long-term growth potential, with current valuation metrics like a P/E of 30.75 reflecting premium pricing justified by its market leadership and earnings trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
